Looks like this event has already ended.
Check out upcoming events by this organizer, or organize your very own event.
Futures in Life Sciences Program - Finance, Legal, and Operations
Tuesday, November 20, 2012 from 5:30 PM to 8:00 PM (EST)
Cambridge, United States
If you are a MA-based full time student interested in attending this event, financial assistance is available through the Stay in MA program. Please visit www.stayinma.com
Futures in Life Sciences -Finance, Legal, and Operations
Panel Discussion and Networking Event
Are you a current graduate student (MBA, MPH, JD, Eng, Ph.D., MD etc,), post doctoral fellow, or medical resident, interested in learning about the importance of intellectual property and other legal considerations for the success of biotechnology and pharmaceutical companies? Are you interested in understanding the various finance focused roles that exist in the life sciences industry for individuals with advanced degrees? Are you looking to learn more about career paths in the operational side of the industry ranging from laboratory setup for startups to leading all aspects of a firms strategy, growth and development. Are you looking to learn more about what types of opportunities exist at larger pharmaceutical firms compared to entrepreneurial firms and how individuals have successfully navigated career paths in both areas. If the answer to the above is yes, then join us on November 20th 2012 for the 8th event in the 2012 Futures in Life Science Series which will cover information about and career paths in the legal, finance and operational areas of the life sciences sector.
Date: November 20th, 2012
Location: MassBio Offices, Cambridge, MA
Time: 5:30pm – 8:00pm
Propel Careers, MassBio, and the MassBioEd have joined together to organize a series of networking and panel events focused on raising awareness of career paths that exist in life sciences for individuals with advanced degrees. This Futures in Life Science program will bring together experts across a wide range of disciplines and functional areas within the life science industry, who will detail their roles and will provide a rich context for the audience to gain a clear understanding of the skills, aptitudes, competencies, and personalities that thrive in their particular functions.
Attendance for this program is open to current graduate students, post doctoral fellows, and medical residents who are interested in careers in the life sciences industry. Space is limited to 100 individuals.
The event will focus on the various career options within the Finance, Legal, and Operations area of the life sciences sector.
5:30pm-6:00pm– Registration and Open Networking
6:00pm-6:10pm – Introductions, Overview, and Recognition of Sponsors
6:10pm-7:30pm – Panel Discussion
Moderator: John Hession, J.D., Partner, Cooley LLP
- Tony Martignetti, Corporate Controller, Sarepta Therapeutics
- Drew Lowery, Biotechnology Group Leader, Global Prior Art
- Joanne Kamens, Executive Director, Addgene
- Stephen Garbacz, Sr. Director of Finance, Epizyme
7:30pm-8:00pm – Open Networking
Moderator and Panel Biographies
John Hession,J.D., Partner Venture Capital Financings and Emerging Companies practice groups, Cooley LLP
John Hession is a partner in the Venture Capital Financings and Emerging Companies practice groups. He was previously the founding Managing Partner of Cooley’s Boston office, helping to spearhead Cooley’s foray into the Boston market in July 2007, and he helped triple the size of the Boston office in three years. Within only three years with a Boston footprint, U.S. News & World Reports ranked Cooley’s Boston office in 2010 as in the Top Tier of law firms for Technology Law and also Venture Capital Law, two areas in which John specializes. He represents emerging-growth technology companies, principally in the medical device, life sciences, software, and digital media fields, as well as angels and venture capital funds in the investment and growth process in these sectors. John’s clients include academic medical centers for technology incubation and company creation projects, entrepreneurs in the company creation and growth process, and venture capital funds and angel investors in financings of emerging- growth companies. His practice includes both start-up and later-stage company work; equity-based compensation strategies; mergers and acquisitions, representing either buyers or sellers; corporate partnering, joint ventures and other strategic alliances involving technology transfers; license and distribution arrangements for medical devices and biotechnology products, software, digital content, hardware, and semiconductors; and venture capital financings of technology enterprises, representing either funds or companies. During his twenty-seven-year career, John has participated in, structured and negotiated more than 300 venture and angel financings; more than 250 strategic alliances involving technology transfers, joint ventures and commercialization projects; 20 public offerings; and 240 acquisitions ranging in size from $1.0 million to $4.2 billion. He has served as an adviser to more than 300 technology companies during his career. John began his legal career at Testa, Hurwitz & Thibeault, where he practiced for 21 years as one of the principal attorneys at Testa representing venture-backed technology companies. Before he joined the legal profession, John was a sales representative with Burroughs Corporation, a Fortune 500 manufacturer of computer hardware, where he achieved Burroughs’ Legion of Honor award for one of the top-performing sales representatives, a high school English teacher, and a carpenter in Ireland. John received his law degree, cum laude, from Boston College Law School, and graduated with his B.A., summa cum laude and as a member of Phi Beta Kappa, from the University of Notre Dame.
Tony Martignetti, Corporate Controller, Sarepta Therapeutics
Tony Martignetti is presently the corporate controller for Sarepta Therapeutics, a biotech company focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit www.sareptatherapeutics.com. In this role, he am responsible for the both the Finance and Accounting operations of the company. He is accountable for the production of periodic SEC, government and internal financial reports, maintenance of an adequate system of accounting records, and a comprehensive set of controls and budgets designed to mitigate risk, enhance the accuracy of the company's reported financial results, and ensure that reported results comply with generally accepted accounting principles. He previously worked as the Associate Director of Commercial Finance, Vertex Pharmaceuticals, Associate Director of Business Unit Finance, Genzyme Corporation, Senior Financial Analyst, ModusLink, and Financial Analyst / General Ledger Accountant, Procter & Gamble (The Gillette Company). He has an MBA Degree in High Technology with a concentration in International Business from Northeastern University a Certification for Economies in Transition, program took place in Czech Republic, Poland and Hungary at Helsinki University of Technology, and a BS Degree in Business Administration with a concentration in Accounting from Northeastern University. He has a deep passion for the life sciences industry because he is fascinated by what we collective do and how it translates into a real impact on patients’ lives. From his first patient visit, he knew that he could no longer work in another industry.
Stephen Garbacz, Sr. Director Finance, Epizyme
Stephen Garbacz is presently the Sr. Director Finance at Epizyme, a new biopharma company that is creating personalized therapeutics and companion diagnostics for patients with genetically defined cancers. The company is developing small molecule inhibitors of Histone Methyl Transferases (HMT’s) that target a 96-member epigenetic class prioritized by genetic disease association. He has been working at Epizyme since August 2012 and have been focused on preparing the finance organization for the future, including being ready for a potential IPO. Prior to Epizyme, he has extensive experience building international organizations at Biogen Idec and Kraft Foods. He has an MBA from New York University and a B.S. Economics from George Mason University. He is passionate about this industry since there is no other industry as rewarding as life sciences, where R&D and entrepreneurial talent combine to address horrible unmet medical needs.
Joanne Kamens, PhD, Executive Director, Addgene
Joanne Kamens PhD, is presently the Executive Director at Addgene. Dr. Kamens received her PhD in Genetics from Harvard Medical School then spent 15 years at BASF/Abbott where she led discovery research projects on small molecule and antibody approaches to inflammatory diseases, ultimately serving as Group Leader in Molecular Biology. In 2007 she joined RXi Pharmaceuticals as Director of Discovery and concluded there as Senior Director of Research Collaborations. In 2011, Dr. Kamens became the Executive Director of Addgene, a mission driven, non-profit dedicated to helping scientists around the world collaborate. She has been raising awareness of women scientists since 1998 upon realizing that an entire week had gone by at work and not one other woman had been at any meeting she attended. Dr. Kamens founded the Boston chapter of AWIS and serves as a Director at large for the Healthcare Businesswomen’s Association Boston Chapter. Follow her on Twitter: @jkamens
Drew Lowery, Ph. D., Director of Life Sciences, Global Prior Art
Drew Lowery, Ph. D. is currently the Director of Life Sciences at Global Prior Art. Global Prior Art is a world leader in the Intellectual Property search and analysis field performing prior art, FTO, acquisition due diligence, and IP landscape analysis projects for leading law firms, companies, and universities. Dr. Lowery received his Ph.D. in Biochemistry from the Massachusetts Institute of Technology where his research focused on phosphorylation-dependent signaling networks involved in cell-cycle control. He has a BS in Biochemistry and Molecular Biology from Pennsylvania State University.
About the Organizers
MassBio - MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services. To learn more, visit: http://www.massbio.org.
MassBioEd - The Massachusetts Biotechnology Education Foundation, founded in 2001, is a non-profit charitable organization committed to supporting science and biotechnology education in Massachusetts through school programs, workforce training, and lifelong learning. MassBioEd is closely affiliated with the Massachusetts Biotechnology Council and helps the Council in fulfilling its goals to nurture the STEM (science, technology, engineering, and math) pipeline in Massachusetts. To learn more, visit http://www.massbioed.org.
Propel Careers - Propel Careers is a Boston based life sciences search and career development firm founded in 2009 to foster entrepreneurship and to cultivate leaders in the life sciences industry. Propel recognizes the importance of job creation and career development opportunities to the success of the industry as well as to next generation of industry leaders. The mission of Propel Careers is to make connections that fuel innovation, and we do this through placement, networking, coaching and mentorship. To learn more, visit http://www.propelcareers.com.